Stockscreener 앱 받기
22.07
6.84%
-1.62
시간 외 거래:
22.50
0.43
+1.95%
전일 마감가:
$23.69
열려 있는:
$22.82
하루 거래량:
1.20M
Relative Volume:
2.04
시가총액:
$1.43B
수익:
$87.56M
순이익/손실:
$-167.47M
주가수익비율:
-9.4316
EPS:
-2.34
순현금흐름:
$-148.20M
1주 성능:
-25.49%
1개월 성능:
-28.06%
6개월 성능:
-48.75%
1년 성능:
-39.10%
1일 변동 폭
$21.40
$22.99
1주일 범위
$21.40
$28.75
52주 변동 폭
$21.40
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
22.07 | 1.43B | 87.56M | -167.47M | -148.20M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
(KYMR) Trading Report - news.stocktradersdaily.com
Teacher Retirement System of Texas Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera stock touches 52-week low at $28.75 amid market challenges - Investing.com Australia
Swiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera at H.C. Wainwright Conference: Strategic Moves in Immunology By Investing.com - Investing.com Canada
Victory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Analyzing Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq
(KYMR) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Why Kymera Therapeutics’ Stock is Making Waves - TipRanks
Kymera at TD Cowen Conference: Focus on Clinical Advancements By Investing.com - Investing.com UK
Don't Ignore The Insider Selling In Kymera Therapeutics - Simply Wall St
Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook - Yahoo Finance
What is B. Riley’s Forecast for KYMR FY2025 Earnings? - Defense World
A Guide To The Risks Of Investing In Kymera Therapeutics Inc (KYMR) - Knox Daily
New York State Common Retirement Fund Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Equities Analysts Offer Predictions for KYMR Q1 Earnings - Defense World
Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World
Kymera Therapeutics announces new performance-based stock plan By Investing.com - Investing.com Australia
Kymera Therapeutics COO sells $42,113 in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics’ chief legal officer sells $68,239 in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics CFO sells shares worth $214,219 By Investing.com - Investing.com South Africa
Kymera Therapeutics’ chief medical officer sells shares worth $174,785 By Investing.com - Investing.com Canada
Kymera Therapeutics CFO sells shares worth $214,219 - Investing.com India
Kymera Therapeutics’ chief medical officer sells shares worth $174,785 - Investing.com
Kymera Therapeutics COO sells $42,113 in stock - Investing.com
Kymera Therapeutics announces new performance-based stock plan - Investing.com India
Kymera Therapeutics Grants Performance Stock Units to Executives - TipRanks
Rhumbline Advisers Acquires 1,861 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Q3 Earnings Forecast for KYMR Issued By HC Wainwright - Defense World
Analysts Set Expectations for KYMR Q2 Earnings - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results - MarketBeat
Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 13.9% on Disappointing Earnings - MarketBeat
(KYMR) Trading Signals - Stock Traders Daily
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus - TradingView
Kymera Therapeutics Inc (KYMR) Volatility Hits 9.22%: What Good Investors Need To Be Aware Of - Stocks Register
Kymera Therapeutics stock target cut to $54 by H.C. Wainwright - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript - Insider Monkey
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus.com
Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviews - Benzinga
We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):